Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification
Circulating soluble urokinase receptor (suPAR) was recently identified as one of the causes responsible for native and recurrent focal segmental glomerulosclerosis (FSGS) through overactivation of podocyte β3 integrin. Here, we discuss the management of a patient with very high suPAR serum levels an...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
Mar 1, 2013
|
| In: |
American journal of therapeutics
Year: 2013, Volume: 20, Issue: 2, Pages: 226-229 |
| ISSN: | 1536-3686 |
| DOI: | 10.1097/MJT.0b013e3182811aca |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/MJT.0b013e3182811aca Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/americantherapeutics/Abstract/2013/03000/Management_of_Severe_Recurrent_Focal_Segmental.15.aspx 
|
| Author Notes: | Morath, Christian MD; Wei, Changli MD, PhD; Macher-Goeppinger, Stephan MD; Schwenger, Vedat MD; Zeier, Martin MD; Reiser, Jochen MD, PhD |
| Summary: | Circulating soluble urokinase receptor (suPAR) was recently identified as one of the causes responsible for native and recurrent focal segmental glomerulosclerosis (FSGS) through overactivation of podocyte β3 integrin. Here, we discuss the management of a patient with very high suPAR serum levels and FSGS recurrence. The suPAR reduction using plasmapheresis and immunoadsorption allowed for lowering of suPAR and reduced podocyte β3 integrin activation and proteinuria. The patient is successfully weaned to bimonthly suPAR removal treatments with improved renal parameters. In summary, we provide an approach for the successful management of severe recurrent FSGS using available therapies with biomarker guidance. |
|---|---|
| Item Description: | Gesehen am 07.06.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1536-3686 |
| DOI: | 10.1097/MJT.0b013e3182811aca |